Autoimmune encephalitis: Should we consider third‐line immunotherapies earlier?

S.R.I. receives licensed royalties on patent application WO/2010/046716, entitled "Neurological Autoimmune Disorders", and has filed two other patents, currently without licencees (WO2022189788A1 and US20210071249A1). S.R.I. has received honoraria from UCB, Roche, Janssen, and Cerebral therapeutics, and research support from CSL Behring, Janssen, UCB, and ONO Pharma. Data sharing is not applicable to this article, as no new data were created or analysed in this study.